Crossmark Global Holdings Inc. Sells 1,461 Shares of DexCom, Inc. (NASDAQ:DXCM)

Crossmark Global Holdings Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCMFree Report) by 7.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 18,965 shares of the medical device company’s stock after selling 1,461 shares during the period. Crossmark Global Holdings Inc.’s holdings in DexCom were worth $2,354,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital Research Global Investors boosted its stake in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Sands Capital Management LLC lifted its holdings in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after buying an additional 1,398,136 shares in the last quarter. Capital World Investors boosted its position in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares during the period. Artisan Partners Limited Partnership boosted its position in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares during the period. Finally, Blair William & Co. IL grew its stake in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after acquiring an additional 73,654 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DXCM shares. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Raymond James upped their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Finally, StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Sunday, June 2nd. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $140.94.

Check Out Our Latest Research Report on DXCM

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 187,293 shares of company stock worth $25,295,452. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $115.79 on Friday. The company has a 50 day moving average price of $129.67 and a 200 day moving average price of $125.66. The firm has a market capitalization of $46.05 billion, a P/E ratio of 74.70, a PEG ratio of 2.88 and a beta of 1.22. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCMGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Sell-side analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.